Free Trial
→ URGENT: If you own a home, please review the map below. (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.00
$0.00
▼
$0.10
$16K-0.828,007 shs1 shs
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.00
$0.00
▼
$0.50
$2K4092.582,773 shs116 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$1.26
-5.0%		$2.31
$1.23
▼
$2.91
$5.57M-0.13165,639 shs25,958 shs
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.54
$3K1.7326,051 shs11 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%0.00%0.00%-99.26%-99.65%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00%0.00%-91.07%+900.00%+900.00%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-1.48%-11.33%-46.15%-47.84%-42.42%
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
0.00%+20.00%0.00%+200.00%-99.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.00
$0.00
$0.00
▼
$0.10
$16K-0.828,007 shs1 shs
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$0.00
$0.00
▼
$0.50
$2K4092.582,773 shs116 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$1.26
-5.0%		$2.31
$1.23
▼
$2.91
$5.57M-0.13165,639 shs25,958 shs
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.54
$3K1.7326,051 shs11 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%0.00%0.00%-99.26%-99.65%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00%0.00%-91.07%+900.00%+900.00%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-1.48%-11.33%-46.15%-47.84%-42.42%
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
0.00%+20.00%0.00%+200.00%-99.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
0.00
N/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
1.00
SellN/AN/A
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest LIPO, CLVR, BPTH, and KPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/12/2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
$17.42M0.00N/AN/A$14.02 per share0.00
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$16.02M0.35N/AN/A$4.38 per share0.29
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$536.36K0.01N/AN/A$1.59 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%N/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
-$17.90M-$7.56N/AN/AN/AN/AN/AN/A11/13/2026 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$10.84M-$2.51N/AN/AN/AN/A-63.38%-44.33%N/A
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-$5.02M-$2.42N/AN/AN/A-988.83%-224.08%-172.88%12/2/2026 (Estimated)

Latest LIPO, CLVR, BPTH, and KPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/2/2026N/A
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-$1.28N/AN/AN/A$0.15 millionN/A
11/13/2026N/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
-$10.95N/AN/AN/A$4.05 millionN/A
11/12/2026Q3 2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.38-$0.28+$0.10-$0.28N/A$1.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
N/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
8.97
8.97
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/A
6.21
6.21

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
6.92%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
74.31%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
8.20%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
0.52%
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
32.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Clever Leaves Holdings Inc. stock logo
CLVR
Clever Leaves
2961.76 million1.61 millionNo Data
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
134.42 million4.40 millionNot Optionable
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
74.62 million3.03 millionNot Optionable

Recent News About These Companies

Lipella Pharmaceuticals Begins Chapter 11 Bankruptcy Restructuring Process
March 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lipella-pharmaceuticals-begins-chapter-11-bankruptcy-restructuring-process?utm_source=marketbeat.com&utm_medium=referral
Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11
March 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265106/0/en/lipella-pharmaceuticals-inc-files-voluntary-petitions-for-relief-under-chapter-11.html
Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus
September 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/lipella-pharmaceuticals-announces-positive-final-120000066.html
Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
September 15, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/lipella-pharmaceuticals-to-present-at-zacks-scr-life-sciences-virtual-investor-forum-and-report-final-phase-2a-results-in-oral-lichen-planus-302555853.html
LIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | Morningstar
July 18, 2025  |  morningstar.comM
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - Morningstar
June 27, 2025  |  morningstar.comM
Lipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operations
June 27, 2025  |  bizjournals.comhttps://www.bizjournals.com/pittsburgh/news/2025/06/26/lipella-pharmaceuticals-delisted-from-nasdaq.html
Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
June 26, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-06/65759276-lipella-pharmaceuticals-inc-lipella-pharmaceuticals-issues-letter-from-the-ceo-to-stockholders-following-nasdaq-delisting-399.htm
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
June 25, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/25/3105404/0/en/lipella-pharmaceuticals-issues-letter-from-the-ceo-to-stockholders-following-nasdaq-delisting.html
Nasdaq delists Lipella Pharmaceuticals over rule violations
June 22, 2025  |  investing.comhttps://www.investing.com/news/company-news/nasdaq-delists-lipella-pharmaceuticals-over-rule-violations-93CH-4104368
Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
June 21, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-06/65719233-lipella-pharmaceuticals-inc-lipella-pharmaceuticals-announces-delisting-from-nasdaq-capital-market-399.htm
Lipella stock tumbles after Nasdaq delisting over rule violations
June 20, 2025  |  in.investing.comhttps://in.investing.com/news/stock-market-news/lipella-stock-tumbles-after-nasdaq-delisting-over-rule-violations-93CH-4884124
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
June 20, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/20/3102906/0/en/lipella-pharmaceuticals-announces-delisting-from-nasdaq-capital-market.html
Lipella Pharmaceuticals Inc. Announces Issuance of U.S. Patent for Advanced Detection Method of Interstitial Cystitis
June 17, 2025  |  quiverquant.comQ
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
June 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/17/3100642/0/en/lipella-pharmaceuticals-announces-u-s-patent-issuance-for-diagnostic-technology.html
Lipella Pharmaceuticals extends manufacturing pact with Cook MyoSite
June 5, 2025  |  investing.comhttps://www.investing.com/news/company-news/lipella-pharmaceuticals-extends-manufacturing-pact-with-cook-myosite-93CH-4080537
Lipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite
June 4, 2025  |  contractpharma.comC
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
June 4, 2025  |  prismmediawire.comP
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
June 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/04/3093548/0/en/lipella-pharmaceuticals-re-signs-manufacturing-collaboration-agreement-with-cook-myosite-to-support-lp-310-clinical-development.html
Lipella Pharmaceuticals to appeal Nasdaq noncompliance warning
May 20, 2025  |  bizjournals.comhttps://www.bizjournals.com/pittsburgh/news/2025/05/19/lipella-pharmaceuticals-nasdaq-noncompliance.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.0003 0.00 (0.00%)
As of 11/12/2026

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Clever Leaves stock logo

Clever Leaves NASDAQ:CLVR

Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.

Kiora Pharmaceuticals stock logo

Kiora Pharmaceuticals NASDAQ:KPRX

$1.26 -0.07 (-5.04%)
As of 12:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Lipella Pharmaceuticals stock logo

Lipella Pharmaceuticals NASDAQ:LIPO

$0.0006 0.00 (0.00%)
As of 11/12/2026

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas